<p>箭头制药公司（NASDAQ:ARWR - 获取免费报告）周二股价下跌了 3.9%。该股最低交易价为 66.78 美元，最后交易价为 66.8950 美元。交易期间大约交易了 253,974 股，较日均交易量 2,134,357 股下降了 88%。该股此前收盘价为 69.62 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
<p>ARWR 近期受到多份分析师报告的关注。Chardan Capital 在 12 月 1 日的研究报告中重申了对箭头制药的 “买入” 评级，并给予 60.00 美元的目标价。美国银行在 12 月 9 日的报告中将箭头制药的目标价从 62.00 美元上调至 81.00 美元，并给予该股 “买入” 评级。摩根士丹利在 11 月 26 日的报告中将箭头制药的目标价从 45.00 美元上调至 48.00 美元，并给予公司 “持平” 评级。HC Wainwright 在 12 月 2 日的研究报告中将箭头制药的目标价从 80.00 美元上调至 85.00 美元，并给予该股 “买入” 评级。最后，高盛集团在 11 月 20 日的报告中将箭头制药的目标价从 27.00 美元上调至 48.00 美元，并给予公司 “中性” 评级。两位股票研究分析师给予该股 “强烈买入” 评级，五位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，箭头制药目前的平均评级为 “适度买入”，平均目标价为 61.89 美元。</p>
<p><strong>阅读我们关于箭头制药的最新股票分析</strong></p>
<h2>箭头制药股价下跌 4.3%</h2>
<p>该公司的流动比率为 4.86，速动比率为 4.86，债务与股本比率为 0.43。该股市值为 90.5 亿美元，市盈率为-831.82，贝塔值为 1.28。该公司的 50 日简单移动平均为 52.38 美元，200 日简单移动平均为 33.56 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席执行官 Christopher Richard Anzalone 在 12 月 15 日的交易中出售了 130,000 股公司的股票。该股以 68.85 美元的平均价格出售，总交易额为 8,950,500.00 美元。交易完成后，首席执行官直接持有公司 3,971,255 股股票，价值约为 273,420,906.75 美元。这代表其持股比例减少了 3.17%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，董事 Michael S. Perry 在 12 月 5 日的交易中出售了 16,250 股股票。该股以 61.03 美元的平均价格出售，总交易额为 991,737.50 美元。交易完成后，该董事直接持有公司 115,240 股股票，价值约为 7,033,097.20 美元。此交易代表其持股比例减少了 12.36%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了 368,736 股公司股票，价值 23,670,228 美元。公司内部人士持有公司 4.30% 的股份。</p>
<h2>对箭头制药的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近增加或减少了对 ARWR 的持股。PNC 金融服务集团在第三季度将其在箭头制药的持股增加了 3.1%。PNC 金融服务集团目前持有 10,924 股该生物技术公司的股票，价值 377,000 美元，此前在该期间内购买了 326 股。怀俄明州在第三季度将其在箭头制药的持股增加了 5.6%。怀俄明州目前持有 9,519 股该生物技术公司的股票，价值 328,000 美元，此前在上个季度购买了 504 股。亚利桑那州退休系统在第三季度将其在箭头制药的持股增加了 1.9%。亚利桑那州退休系统目前持有 32,661 股该生物技术公司的股票，价值 1,126,000 美元，此前在上个季度购买了 620 股。CWM LLC 在第三季度将其在箭头制药的持股增加了 6.7%。CWM LLC 目前持有 12,179 股该生物技术公司的股票，价值 420,000 美元，此前在该期间内购买了 764 股。最后，iSAM Funds UK Ltd 在第三季度购买了价值约 29,000 美元的箭头制药新股份。目前 62.61% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>箭头制药公司简介</h2>
<p>（获取免费报告）</p>
<p>箭头制药公司是一家临床阶段的生物制药公司，专注于 RNA 干扰（RNAi）治疗的发现、开发和商业化。自 2008 年成立以来，箭头制药利用其专有的递送平台——内部称为先进 RNAi 化合物（ARC）技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久、针对性的治疗，涵盖多个治疗领域。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的候选药物。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>美国人在 “母矿行动” 中可以瞄准 100%+ 的胜利</li>
<li>特朗普的新人工智能预算刚刚通过——一只股票可能会飙升</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>传奇投资者发出令人不安的警告</li>
<li>特朗普取消美国一分币的可怕原因？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
<p>在考虑箭头制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而箭头制药并不在名单上。</p>
<p>虽然箭头制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

箭头制药

<p>箭头制药 (NASDAQ:ARWR) 的股价下跌了 3.9%，至 66.8950 美元，交易量较平均水平下降了 88%。分析师的评级不一，Chardan Capital 给予 “买入” 评级，且美国银行将目标价上调至 81.00 美元。公司内部人士最近出售了大量股份，包括首席执行官 Christopher Anzalone。机构投资者持有 62.61% 的股份。该公司专注于 RNA 干扰治疗，市值为 90.5 亿美元</p>

<p>Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) shares were down 3.9% on Tuesday . The stock traded as low as $66.78 and last traded at $66.8950. Approximately 253,974 shares were traded during trading, a decline of 88% from the average daily volume of 2,134,357 shares. The stock had previously closed at $69.62.</p>
<div class="lb-trans"><p>箭头制药公司（NASDAQ:ARWR - 获取免费报告）周二股价下跌了 3.9%。该股最低交易价为 66.78 美元，最后交易价为 66.8950 美元。交易期间大约交易了 253,974 股，较日均交易量 2,134,357 股下降了 88%。该股此前收盘价为 69.62 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Want Diversified Upside in Biotechnology? Check out LABU</li>
</ul>
<div class="lb-trans"><ul>
<li>想要在生物技术领域获得多元化的上涨潜力？查看 LABU</li>
</ul>
</div><p>ARWR has been the subject of several recent analyst reports. Chardan Capital restated a &#34;buy&#34; rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, December 1st. Bank of America increased their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, December 9th. Morgan Stanley lifted their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an &#34;equal weight&#34; rating in a report on Wednesday, November 26th. HC Wainwright boosted their target price on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a &#34;buy&#34; rating in a research report on Tuesday, December 2nd. Finally, The Goldman Sachs Group raised their price target on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, November 20th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $61.89.</p>
<div class="lb-trans"><p>ARWR 近期受到多份分析师报告的关注。Chardan Capital 在 12 月 1 日的研究报告中重申了对箭头制药的 “买入” 评级，并给予 60.00 美元的目标价。美国银行在 12 月 9 日的报告中将箭头制药的目标价从 62.00 美元上调至 81.00 美元，并给予该股 “买入” 评级。摩根士丹利在 11 月 26 日的报告中将箭头制药的目标价从 45.00 美元上调至 48.00 美元，并给予公司 “持平” 评级。HC Wainwright 在 12 月 2 日的研究报告中将箭头制药的目标价从 80.00 美元上调至 85.00 美元，并给予该股 “买入” 评级。最后，高盛集团在 11 月 20 日的报告中将箭头制药的目标价从 27.00 美元上调至 48.00 美元，并给予公司 “中性” 评级。两位股票研究分析师给予该股 “强烈买入” 评级，五位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，箭头制药目前的平均评级为 “适度买入”，平均目标价为 61.89 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Arrowhead Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于箭头制药的最新股票分析</strong></p>
</div><h2>Arrowhead Pharmaceuticals Trading Down 4.3%</h2>
<div class="lb-trans"><h2>箭头制药股价下跌 4.3%</h2>
</div><p>The company has a current ratio of 4.86, a quick ratio of 4.86 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $9.05 billion, a price-to-earnings ratio of -831.82 and a beta of 1.28. The business has a 50 day simple moving average of $52.38 and a 200-day simple moving average of $33.56.</p>
<div class="lb-trans"><p>该公司的流动比率为 4.86，速动比率为 4.86，债务与股本比率为 0.43。该股市值为 90.5 亿美元，市盈率为-831.82，贝塔值为 1.28。该公司的 50 日简单移动平均为 52.38 美元，200 日简单移动平均为 33.56 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Christopher Richard Anzalone sold 130,000 shares of the company's stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the completion of the transaction, the chief executive officer directly owned 3,971,255 shares of the company's stock, valued at approximately $273,420,906.75. This represents a 3.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 16,250 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the completion of the sale, the director directly owned 115,240 shares in the company, valued at approximately $7,033,097.20. This trade represents a 12.36% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 368,736 shares of company stock worth $23,670,228. Corporate insiders own 4.30% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Christopher Richard Anzalone 在 12 月 15 日的交易中出售了 130,000 股公司的股票。该股以 68.85 美元的平均价格出售，总交易额为 8,950,500.00 美元。交易完成后，首席执行官直接持有公司 3,971,255 股股票，价值约为 273,420,906.75 美元。这代表其持股比例减少了 3.17%。该交易已在向证券交易委员会提交的文件中披露，相关文件可通过 SEC 网站访问。此外，董事 Michael S. Perry 在 12 月 5 日的交易中出售了 16,250 股股票。该股以 61.03 美元的平均价格出售，总交易额为 991,737.50 美元。交易完成后，该董事直接持有公司 115,240 股股票，价值约为 7,033,097.20 美元。此交易代表其持股比例减少了 12.36%。该销售的 SEC 文件提供了更多信息。在过去三个月中，内部人士共出售了 368,736 股公司股票，价值 23,670,228 美元。公司内部人士持有公司 4.30% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Arrowhead Pharmaceuticals</h2>
<div class="lb-trans"><h2>对箭头制药的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. PNC Financial Services Group Inc. increased its holdings in shares of Arrowhead Pharmaceuticals by 3.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company's stock valued at $377,000 after purchasing an additional 326 shares during the period. State of Wyoming grew its position in Arrowhead Pharmaceuticals by 5.6% during the third quarter. State of Wyoming now owns 9,519 shares of the biotechnology company's stock valued at $328,000 after purchasing an additional 504 shares in the last quarter. Arizona State Retirement System grew its position in Arrowhead Pharmaceuticals by 1.9% during the third quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company's stock valued at $1,126,000 after purchasing an additional 620 shares in the last quarter. CWM LLC increased its stake in Arrowhead Pharmaceuticals by 6.7% in the 3rd quarter. CWM LLC now owns 12,179 shares of the biotechnology company's stock valued at $420,000 after buying an additional 764 shares during the period. Finally, iSAM Funds UK Ltd purchased a new stake in Arrowhead Pharmaceuticals in the 3rd quarter worth approximately $29,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对 ARWR 的持股。PNC 金融服务集团在第三季度将其在箭头制药的持股增加了 3.1%。PNC 金融服务集团目前持有 10,924 股该生物技术公司的股票，价值 377,000 美元，此前在该期间内购买了 326 股。怀俄明州在第三季度将其在箭头制药的持股增加了 5.6%。怀俄明州目前持有 9,519 股该生物技术公司的股票，价值 328,000 美元，此前在上个季度购买了 504 股。亚利桑那州退休系统在第三季度将其在箭头制药的持股增加了 1.9%。亚利桑那州退休系统目前持有 32,661 股该生物技术公司的股票，价值 1,126,000 美元，此前在上个季度购买了 620 股。CWM LLC 在第三季度将其在箭头制药的持股增加了 6.7%。CWM LLC 目前持有 12,179 股该生物技术公司的股票，价值 420,000 美元，此前在该期间内购买了 764 股。最后，iSAM Funds UK Ltd 在第三季度购买了价值约 29,000 美元的箭头制药新股份。目前 62.61% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Arrowhead Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>箭头制药公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.</p>
<div class="lb-trans"><p>箭头制药公司是一家临床阶段的生物制药公司，专注于 RNA 干扰（RNAi）治疗的发现、开发和商业化。自 2008 年成立以来，箭头制药利用其专有的递送平台——内部称为先进 RNAi 化合物（ARC）技术——来沉默患有遗传性疾病的患者体内致病基因。该公司的方法旨在提供持久、针对性的治疗，涵盖多个治疗领域。</p>
</div><p>The company's pipeline includes multiple candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Arrowhead Pharmaceuticals</li>
<li>Americans can target 100%+ wins during “Operation Motherlode”</li>
<li>Trump’s new AI budget just passed — one stock could soar</li>
<li>Wall Street Stockpicker Names #1 Stock of 2026</li>
<li>Chilling warning from legendary investor</li>
<li>Terrifying reason Trump killed the U.S. penny?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比箭头制药更好</li>
<li>美国人在 “母矿行动” 中可以瞄准 100%+ 的胜利</li>
<li>特朗普的新人工智能预算刚刚通过——一只股票可能会飙升</li>
<li>华尔街股票挑选者命名 2026 年第一只股票</li>
<li>传奇投资者发出令人不安的警告</li>
<li>特朗普取消美国一分币的可怕原因？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Arrowhead Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在箭头制药吗？</h2>
</div><p>Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑箭头制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而箭头制药并不在名单上。</p>
</div><p>While Arrowhead Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然箭头制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

箭头制药（NASDAQ:ARWR）股价下跌 3.9% - 现在是卖出的时候吗？